Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients with Advanced Non-small Cell Lung Cancer

First Posted Date
2021-12-02
Last Posted Date
2024-11-21
Lead Sponsor
BioNTech SE
Target Recruit Count
160
Registration Number
NCT05142189
Locations
🇺🇸

Norton Cancer Institute, Louisville, Kentucky, United States

🇺🇸

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

NEXT Virginia, Fairfax, Virginia, United States

and more 35 locations

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-11-24
Last Posted Date
2024-11-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
95
Registration Number
NCT05132075
Locations
🇺🇸

Valley Medical Center Research Valley Professional Center Bld, Renton, Washington, United States

🇺🇸

Valley Medical Center Research, Renton, Washington, United States

🇻🇳

Novartis Investigative Site, Hanoi, Vietnam

Neoadjuvant Treatment of Breast Cancer

First Posted Date
2021-11-23
Last Posted Date
2021-11-23
Lead Sponsor
National Institute of Oncology, Hungary
Target Recruit Count
300
Registration Number
NCT05131893
Locations
🇭🇺

National Institute of Oncolgy, Budapest, Hungary

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

First Posted Date
2021-11-18
Last Posted Date
2023-11-22
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
80
Registration Number
NCT05125055
Locations
🇨🇳

Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

First Posted Date
2021-11-11
Last Posted Date
2021-12-07
Lead Sponsor
Brown University
Registration Number
NCT05116800
Locations
🇺🇸

Lifespan Cancer Insitute, Providence, Rhode Island, United States

🇺🇸

Hasbro Children's Hospital, Providence, Rhode Island, United States

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

First Posted Date
2021-11-10
Last Posted Date
2024-11-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
616
Registration Number
NCT05116189
Locations
🇺🇸

University of Massachusetts Chan Medical School-Division of Gynecologic Oncology ( Site 0003), Worcester, Massachusetts, United States

🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0007), Hackensack, New Jersey, United States

🇨🇦

BC Cancer Victoria ( Site 0513), Victoria, British Columbia, Canada

and more 184 locations

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

First Posted Date
2021-11-03
Last Posted Date
2023-08-16
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
1
Registration Number
NCT05106335
Locations
🇨🇳

Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu, China

A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors

First Posted Date
2021-10-26
Last Posted Date
2024-12-13
Lead Sponsor
Amgen
Target Recruit Count
649
Registration Number
NCT05094336
Locations
🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

California Research Institute, Glendale, California, United States

and more 66 locations

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

First Posted Date
2021-10-26
Last Posted Date
2023-11-02
Lead Sponsor
OncoResponse, Inc.
Target Recruit Count
172
Registration Number
NCT05094804
Locations
🇺🇸

NEXT Oncology, San Antonio, Texas, United States

🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

NEXT Austin, Austin, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath